How many investments has Catalys Pacific made?

Catalys Pacific has 7 tracked investments, 1 of which have exited via acquisition or IPO.

What stage does Catalys Pacific invest at?

Catalys Pacific invests at the Seed, Series A stages.

What sectors does Catalys Pacific focus on?

Catalys Pacific focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Catalys Pacific located?

Catalys Pacific is headquartered in Tokyo, JP.

Who does Catalys Pacific co-invest with?

Catalys Pacific most often shares deals with Frazier Life Sciences, RA Capital, Lightspeed Venture Partners, among 8 tracked co-investors.

Catalys Pacific

Venture capital

Tokyo · Seed–Series A · 26 people tracked

Also known as CATALYS PACIFIC, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Catalys Pacific centers its investment and company-building strategy on transpacific partnerships, combining an extensive global network with on-the-ground local presence in both Japan and the United States. This dual presence enables differentiated deal sourcing and access to early-stage opportunities to found and build bespoke new biotech companies on both sides of the Pacific. The firm aims to maximize therapeutic impact for patients worldwide while generating attractive risk-adjusted returns for investors, focusing on creating innovation for patients through precision therapeutics and drug development.

Invests inBiotech Digital Health Healthtech Medical Devices Asia-Pacific Japan North America Tokyo United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Series A

Tokyo, JP

Instruments

Equity

Founded

2019

Private fund assets

$1.1B

VC funds

Tracked investments

Team · 26 people

from the firm's website & curated & public directories

Brian Taylor Slingsby· Founder & Managing Director, MD, PhD, MPH

Physician-scientist and biotech entrepreneur who leads Catalys Pacific's company creation efforts, having founded and led numerous therapeutics companies including Mineralys, Pathalys, Crystalys and Kirilys. He previously founded and led the GHIT Fund and worked as an executive at Eisai. He holds degrees from Brown, Kyoto University, University of Tokyo and George Washington University.

BT Slingsby· Founder & Managing Director

Founder and Managing Director of Catalys Pacific; holds MD, PhD and MPH degrees.

b•••@catalyspacific.comreveal

Ashwin Ram· Partner

a•••@catalyspacific.comreveal

Ryutaro Shimazaki· Partner

Ryutaro is a Partner at Catalys Pacific. He previously served as Executive Officer and Global Head of Nephrology R&D at Kyowa Kirin, where he led the development and regulatory filings of medicines including Darbepoetin alfa, Evocalcet, Pegfilgrastim, and Burosumab, and oversaw more than 10 product launches across Japan and East Asia. He is a graduate of Tokyo University of Science and a qualified pharmacist.

r•••@catalyspacific.comreveal

Sandy Mong· Partner, MD

Sandy Mong is a Partner at Catalys Pacific with experience in business development, corporate strategy, and program leadership across therapeutic areas from discovery to clinical stage. She previously held BD and operations roles at Mariana Oncology (acquired by Novartis), BridgeBio Pharma, and CRISPR Therapeutics, and was a consultant at McKinsey. She holds an MD from Harvard Medical School and a B.S. from Yale University.

s•••@catalyspacific.comreveal

Takeshi Takahashi· Managing Director· Japanin

Managing Director at Catalys Pacific with healthcare M&A, IPO, and financing expertise. Previously spent 12 years in Morgan Stanley's investment banking division working on major transactions, and earlier managed a fixed income portfolio at Merrill Lynch's asset management division. Holds a degree from Waseda University and an MBA from Kellogg School of Management at Northwestern University.

t•••@catalyspacific.comreveal

Jogen Atone· Principal

Hiromi Miwa· Principal· Tokyo, Tokyo, Japanin

h•••@catalyspacific.comreveal

Yoshiro Banno· Principal

y•••@catalyspacific.comreveal

Yuki Makihira· Vice President

Yuki Makihira is a Vice President at Catalys Pacific. She previously worked in Goldman Sachs's investment banking division on financing and M&A, and has experience in the sports industry, including establishing a sports club, its internet media business, and business operations. She holds a B.A. in Political Science from Keio University's Faculty of Law.

y•••@catalyspacific.comreveal

Jay Shepard· Venture Partner· New York, New York, United Statesin

Ariel Miura· Analyst

Hayato Urabe· Vice President

Vice President at Catalys Pacific; holds PhD and MPIA degrees.

Hidemasa Tanigaki· Operating Partner· Tokyo, Japanin

Jon Congleton· Operating Partner

Jonathan MacQuitty· Advisor

Advisor to Catalys Pacific; holds a PhD.

Masato Iwasaki· Advisor

Advisor to Catalys Pacific; holds a PhD.

Mitsuyuki “Mickey” Matsumoto· Operating Partner

Operating Partner at Catalys Pacific; holds a PhD.

Neal Fowler· Operating Partner

Operating Partner at Catalys Pacific; holds an MBA.

Nobuo Hanai· Advisor

Advisor to Catalys Pacific; holds a PhD.

Norihiko Ishihara· Advisor

Ryan Drant· Advisor

Seth H Z Fischer· Advisor

Maki Haginoya· Vice President

Maki Haginoya is a Vice President at Catalys Pacific with legal expertise and a background in pharmaceutical business development. She previously worked at Sato Pharmaceutical on licensing of healthcare products, contract negotiation, and alliance management, and holds a B.A. in law from Keio University.

m•••@catalyspacific.comreveal

Megumi Nagata· Associate

m•••@catalyspacific.comreveal

Krishna Polu· Advisor· San Francisco Bay Areain

Founder mafia

2 people who came through Catalys Pacific went on to found or lead other companies.

Brian Taylor SlingsbyFounder & Managing Director, MD, PhD, MPHFounded Mineralys Therapeutics Krishna PoluAdvisorFounded Commit Biologics

What they invest in

from 8 of 11 portfolio companies

Biotech ×8Healthtech ×5Medical Devices ×2Fintech ×1

HQs:United States×6Japan×1

Investments · 11 tracked

founders shown can be your intro path

By year:2024 · 1 2022 · 1 2020 · 13 dated

Mineralys Therapeuticsmineralystx.com in 𝕏NASDAQ: MLYSJun 2022SEC filinghigh confidence

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)Alex Gold(Chief Medical Officer)Adam Levy(Executive Officer)Alexander Asam(Director)

BoardOlivier Litzka(Director)in

Board seatTakeshi TakahashiBrian Taylor Slingsby· per SEC Form D · $118M raise · filed Jun 2022

Co-investorsAndera Partners Samsara BioCapital SR One Capital Management Ysios Capital Boulder Ventures RA Capital

Arialysarialysrx.com in 𝕏✓ verified

Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.

BiotechHealthtechLa Jolla, US

Peter Flynn, Ph.D.(Executive Officer, Director)

BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)

Co-investorsAvalon BioVentures MPM BioImpact

Crystalystxcrystalystx.com in 𝕏✓ verified

Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.

BiotechHealthtechMedical DevicesSan Diego, US

James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in

Co-investorsNovo Holdings AN Venture Partners Frazier Life Sciences Lightstone Ventures Longwood Fund

ヘパリスファーマ株式会社hepalys.com✓ verified

Hepalys Pharma is a late-stage biopharmaceutical company developing innovative therapeutics for liver disease in Japanese and Asian patients, focusing on metabolic dysfunction-associated steatohepatitis (MASH) treatment through its lead candidate Lanifibranor.

BiotechMedical DevicesTokyo, JP

Co-investorsNippon Venture Capital

Exalys TherapeuticsApr 2020SEC filinghigh confidence

BiotechSan Diego, US

Eckard Weber, M.D.(Director)Michael Sanders(Executive Officer)Nicole Vitullo(Director)Dennis Podlesak(Executive Officer, Director)Rick Orr(Director)Lynne Rollins(Executive Officer)

Board seatTakeshi TakahashiBrian Taylor Slingsby· per SEC Form D · $25M raise · filed Apr 2020

Aculys

Company addressing social issues in neurology (noted as acquired).

HilleVaxhillevax.com inacquired by XOMA Royalty

BiotechFintech

Co-investorsFrazier Life Sciences Lightspeed Venture Partners RA Capital Samsara BioCapital

Kirilys

A multi-asset precision oncology company

Mineralys

A targeted approach for the control of hypertension

Co-investorsRA Capital

Pathalyspathalys.com in 𝕏Aug 2024 · $105M

Pathalys Pharma is a private biopharmaceutical company developing treatments for kidney disease, including upacicalcet, which is in late-stage development.

BiotechHealthtechResearch Triangle Park, US

Co-investorsOrbiMed Samsara BioCapital Abingworth KB Investment

Phathom Pharmaceuticalsphathompharma.com in 𝕏

Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.

BiotechHealthtech

Mr. Basta(CEO)

Co-investorsFrazier Life Sciences New Enterprise Associates (NEA)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 2

IPOs and acquisitions across the tracked portfolio

Mineralys TherapeuticsNASDAQ: MLYSHilleVaxacq. by XOMA Royalty

Portfolio news

latest coverage across their companies

Mineralys Builds $661 Million War Chest Ahead of FDA Decision - MyChesCo

Mineralys Therapeutics · mychesco.com · Aug 18, 2026

Arialys' precision therapy shows promise in rare encephalitis disorder and beyond

Arialys · fiercebiotech.com · Jun 20, 2025

Public market activity · per SEC filings

what is this? ⓘ

Files 13F institutional holdings reports · latest Aug 2026

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Catalys Pacific made?: Catalys Pacific has 7 tracked investments, 1 of which have exited via acquisition or IPO.
What stage does Catalys Pacific invest at?: Catalys Pacific invests at the Seed, Series A stages.
What sectors does Catalys Pacific focus on?: Catalys Pacific focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Catalys Pacific located?: Catalys Pacific is headquartered in Tokyo, JP.
Who does Catalys Pacific co-invest with?: Catalys Pacific most often shares deals with Frazier Life Sciences, RA Capital, Lightspeed Venture Partners, among 8 tracked co-investors.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M